Tempest Therapeutics Q1 2024 GAAP EPS $(0.36) Beats $(0.37) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics reported Q1 2024 GAAP EPS of $(0.36), surpassing the consensus estimate of $(0.37) by 2.7%.
May 09, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tempest Therapeutics reported a smaller-than-expected quarterly loss of $(0.36) per share, beating the consensus estimate of $(0.37).
Beating earnings estimates typically leads to positive investor sentiment and can cause a short-term increase in stock price. The beat, although slight, indicates better-than-expected financial health and performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100